TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who has been receiving a stable dose and regimen of insulin over 12 weeks before administration of investigational drug~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug~* Patients whose HbA1c is between 7.5% and 10.5%~* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug.~Exclusion Criteria:~* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)~* Patients who are accepting treatments of arrhythmias~* Patients with serious diabetic complications~* Patients who are the excessive alcohol addicts~* Patients with severe hepatic disorder or severe renal disorder.~* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teneli (Teneligliptin) /Teneli + insulin (Type: EXPERIMENTAL): Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
- Placebo/Teneli (Teneligliptin) + insulin (Type: PLACEBO_COMPARATOR): Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* no response or \< 25% reduction in subjective nocturia by the IPSS question 7 after 4-weeks of treatment with terazosin~* no response or \< 25% reduction in objective nocturia by the FVC after 4-weeks of treatment with terazosin~* nocturia on average two times or more per night (according to the FVC) after 4-weeks of terazosin therapy~Exclusion Criteria:~* use of medications for the control of bladder symptoms~* use of sedatives or tranquillisers for treating sleep disturbances~* bladder tumours~* bladder stones~* urethral strictures~* neurogenic bladder dysfunction~* restricted mobility~* working primarily at night~* a documented history or clinical symptoms of prostatitis, prostate cancer, or prostatic intraepithelial neoplasia on biopsy~* serum PSA levels of \>20 ng/mL~* a history of prostate surgery or radiotherapy, acute urinary retention or an indwelling catheter~* evidence of acute urinary infection (pyuria and bacteriuria)on urine analysis

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Intermediate Cervical Plexus Block for Congenital Muscular Torticollis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II~* Undergoing general anesthesia for unipolar sternocleidomastoid release in patient with congenital muscular torticollis~Exclusion Criteria:~* coagulation disorder~* kidney or liver disease~* allergy to local anesthetics

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Block (Type: EXPERIMENTAL): ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg.~Fentanyl in postanesthesia care unit(PACU), Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4.
- No block (Type: PLACEBO_COMPARATOR): Fentanyl in PACU, Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Protocols for Patients With Symptomatic Oral Lichen Planus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years;~* clinical diagnosis and histological diagnosis of OLP on the basis of WHO criteria;~* presence of symptoms related to OLP.~Exclusion Criteria:~* presence of systemic conditions that may have affected the study results;~* state of pregnancy or breastfeeding;~* histological signs of dysplasia;~* drugs inducing a lichen response (ACE-inhibitors, β-blockers, etc.);~* treatment of OLP in the six months prior to the start of the programme;~* presence of extraoral lesions (genital, skin and other)~* history of previous immunodeficiency or HIV seropositivity;~* previous allogeneic bone marrow transplantation;~* presence of systemic lupus erythematosus or other autoimmune diseases.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Clobetasol treatment (Type: ACTIVE_COMPARATOR): The clobetasol group was treated with clobetasol propionate 0.05%, while the anti-inflammatory group was treated with mouthwash. The drug used consisted of Clobetasol propionate 0.05%, Ethyl alcohol 96° (50%), Hydroxyethylcellulose (4%); Preserved water (just enough to 100%) that was topically applied \[11\]. This drug was produced as a galenic formulation. Clobetasol propionate twice a day (every 12 hours) to the lesions with a soft bristle brush and were advised not to drink or eat during the hour following application of the medication.
- Anti-inflammatory mouthwash (Type: ACTIVE_COMPARATOR): In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interscalene Block With Low-dose IV vs. Perineural Dexamethasone for Shoulder Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients having ambulatory arthroscopic shoulder surgery under ultrasound-guided interscalene block (rotator cuffs, acromioplasties, stabilizations, labral repairs, etc.)~* Age 18-70 years~Exclusion Criteria:~* Contraindication to interscalene block~* Known allergy/sensitivity to any study medications~* Having taken daily steroids for 10 days or longer anytime during the past year~* Body mass index \<18 or \>40~* History of uncontrolled nausea and vomiting with opioids or severe post-op nausea and vomiting (to prevent any need for higher doses of IV dexamethasone)~* Non-English speaking~* Revision procedures~* Additional procedures (e.g., removal of hardware, procedures involving other areas, etc.)~* Planned open procedures~* History of diabetes~* Arthroscopic irrigation and debridement secondary to infection~* Peripheral neuropathies affecting the operative extremity~* Having taken opiates daily for 10 days or longer immediately preceding surgery, 3 times a week for greater than 3 months anytime in the past year, or currently taking for anything other than shoulder pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous dexamethasone (Type: ACTIVE_COMPARATOR): Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
- Perineural dexamethasone (Type: EXPERIMENTAL): Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Follow-Up for Discharged Emergency Care Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age 18 years or older,~2. accessible short message service (SMS) capable mobile phone or residential landline,~3. able to read English or have English-speaking family member to assist with phone communications,~4. discharged directly from the Barnes Jewish hospital (St. Louis, MO) emergency department (ED), and~5. given a clinical referral to make an outpatient follow-up appointment at time of discharge to a specific clinic or provider~Exclusion Criteria:~1. unable or refused to provide consent,~2. could not be contacted by a phone call or SMS,~3. non-English speaking,~4. were admitted to the hospital, and~5. already had a follow-up appointment scheduled before being discharged from the ED

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Receiving current standard of care as designated by emergency department (ED) standard operating practice.
- Epharmix/CareSignal eHealth Intervention (Type: EXPERIMENTAL): After randomization, participants receive text reminders to have a follow-up visit. The participant can respond to these messages via numerical or binary answers (Y/N).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Infant Environment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High food reinforcement~Exclusion Criteria:~* born preterm (\<37 weeks gestation)~* a low birth weight (\< 2500 grams)~* known developmental delay(s)~* subject's mother was \< 18 years old at the time of pregnancy~* not yet eating finger foods

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- Music Enhancement (Type: EXPERIMENTAL): 37 weekly Music Together classes for one year, then 12 monthly Music Together classes the following year.
- Play Date (Type: ACTIVE_COMPARATOR): 37 weekly group Play Date sessions for one year, then 12 monthly group Play Date sessions the following year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of at least 5 attacks of migraine without aura and/or migraine with visual sensory, speech and/or language, retinal or brainstem aura.~* History of ≥ 15 headache days per month of which ≥ 8 headache days were assessed by the subject as migraine day.~* ≥ 4 distinct headache episodes, each lasting ≥ 4 hours OR if shorter, associated with use of a triptan or ergot-derivative on the same calendar day based on the eDiary calculations.~* Demonstrated at least 80% compliance with the eDiary.~Exclusion Criteria:~* History of cluster headache or hemiplegic migraine headache~* Unable to differentiate migraine from other headaches~* Failed \> 3 medication categories due to lack of efficacy for prophylactic treatment of migraine .~* Received botulinum toxinin head or neck region within 4 months prior to screening.~* Used a prohibited migraine prophylactic medication, device or procedure within 2 months prior to the start of the baseline phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection.
- Erenumab 70 mg (Type: EXPERIMENTAL): Participants received 70 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
- Erenumab 140 mg (Type: PLACEBO_COMPARATOR): Participants received 140 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Documented HIV-negative according to two fingerpick rapid tests (per routine antenatal care protocol in this setting), confirmed with a 4th generation antigen HIV test at study enrollment~2. No previous exposure triple-drug antiretroviral therapy~3. Age 18 years or older~4. Lives within 20 kilometers of a clinic~5. Without psychiatric or medical contraindications to PrEP use~6. Able to provide informed consent for research~Exclusion Criteria:~Failure to meet any of the inclusion criteria

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age between 18 and 75 years~* Rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria 1987 or ACR/European Liga Against Rheumatology (EULAR)2010~* Disease activity score (DAS) 28 \> 2.6~Main Exclusion Criteria:~* Prior or other current subcutaneous treatment with self-injection~* Prior or concomitant treatment with biologics~* Contraindications to MTX treatment~* History or diagnosis of a dermatological disease at the injection site~* Women with child-bearing potential who do not use a highly effective method of contraception or men who have a partner with child-bearing potential and do not use a contraception during the study and at least 6 months thereafter.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- prefilled pen then prefilled syringe (Type: OTHER): weekly methotrexate injection with a prefilled pen during 3 weeks and subsequently with the prefilled syringe the last 3 weeks
- prefilled syringe then prefilled pen (Type: OTHER): weekly methotrexate injection with a prefilled syringe during 3 weeks and subsequently with the prefilled pen the last 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Paitents with stable CAD referred to elective percutaneous coronary intervention (PCI) of an isolated, functionally significant (as confirmed by a fractional flow reserve \[FFR\] \<0.80) stenosis located in the proximal two-thirds of a major coronary artery~Exclusion Criteria:~* age \<18 years or ≥75 years, body weight \<60 kg, previous transient ischemic attack (TIA) or stroke, acute coronary syndromes, administration of glycoprotein IIb/IIIa inhibitors, platelet count \<70x109/l, high bleeding risk (active internal bleeding, history of haemorrhagic stroke, intracranial neoplasm, arteriovenous malformation or aneurysm, ischemic stroke in the previous 3 months), coronary bypass graft surgery in the previous 3 months, severe chronic renal failure (serum creatinine ≥2 mg/dl), previous myocardial infarction, left ventricular ejection fraction less than 50%, left ventricle wall-motion abnormalities, left ventricular hypertrophy, chronic total occlusion, lesions with extensive calcifications requiring rotational atherectomy, in-stent restenosis, bifurcation lesions with side branch diameter of more than 2 mm, ostial lesion, and contraindications to adenosine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel Group (Type: EXPERIMENTAL): Patient treated with 60 mg prasugrel 12 hours before the procedure
- Ticagrelor (Type: EXPERIMENTAL): Patient treated with 180 mg ticagrelor 12 hours before the procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of overactive bladder with symptoms for at least 6 months.~* Moderate to severe incontinence episode frequency and subsequent sub-optimal response to tolterodine~* Women of child-bearing potential must not intend to become pregnant, be pregnant or producing breast milk at the time of study entry, and must use contraception~Exclusion Criteria:~* Conditions or prior treatment that may also affect bladder function~* Clinically significant urinary tract infection (UTI)~* Ongoing treatment with overactive bladder medications (these can be stopped at the first visit to allow entry into the study).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fesoterodine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Cirrhotic patients, potential candidates for liver transplantation, with indication to HBV vaccination (HBsAg negative and anti-HBs negative).~2. Patients under treatment with HBVAXPRO® who do not show a response after the first cycle of vaccination of three intramuscular doses of 40 µg at 0, 1 and 2 months.~3. Patients over 18 years old.~4. Negative pregnancy test.~5. Patients who have given their consent to participate in the study.~Exclusion Criteria:~1. Absolute contraindication to HBV vaccine.~2. Medical history of allergy to any component of the vaccine.~3. Chronic renal failure on hemodialysis.~4. Presence of antibodies against Human Immunodeficiency Virus.~5. Patients with seroconversion (anti-HBs \> 10 IU /ml) after the first three doses of vaccine.~6. Lack of consent to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Second HBV vaccination cycle (Type: EXPERIMENTAL): Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.
- Single dose of HBV vaccine (Type: ACTIVE_COMPARATOR): Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete